In fact, the presence of a particular subset of IFN-stimulated genes (ISGs) in cancer cells is associated with immune suppression and resistance to ICB by regulating chromatin accessibility, while abrogating Type I IFN or IFNγ signaling in tumor cells improves the function of many immune compartments, such as CD8+ T cells, NK cells, and innate lymphoid cells (Benci et al, 2019; Benci et al, 2016; Qiu et al, 2023; Teijaro et al, 2013; Wilson et al, 2013). This evidence concerns the gene IFNG and cancer.